Voleon Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
Voleon Capital Management's MLTX Position: Q3 2026 in Review
Voleon Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 30% in Q3 2026, selling an estimated $858K and leaving 121,416 shares worth $1.42M. The position accounts for 0.03% of the portfolio, ranked #393.
Voleon Capital Management first reported a position in MLTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $6.95M in Q1 2026. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- Voleon Capital Management held 121,416 shares of MoonLake Immunotherapeutics worth $1.42M as of Q3 2026.
- Voleon Capital Management sold 52,493 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $858K.
- MoonLake Immunotherapeutics made up 0.03% of Voleon Capital Management's portfolio in Q3 2026, its #393 holding.
- Voleon Capital Management first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 5 quarters since.
- Voleon Capital Management's MoonLake Immunotherapeutics position peaked at $6.95M in Q1 2026.
- 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on Voleon Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.